Description
AdipoRon is an agonist at adiponectin receptors that increases secretion of AMPK and PPAR-α. AdipoRon exhibits anti-diabetic and cardioprotective activities and is in development as a potential treatment for type 2 diabetes mellitus (T2DM). In vivo, AdipoRon decreases insulin resistance and glucose tolerance, ameliorates diabetes, and increases lifespan. In animal models of myocardial ischemia/reperfusion, this compound improves cardiac function, decreases oxidative stress, and inhibits post-ischemic cardiomyocyte apoptosis.
